Free Trial

Intellia Therapeutics (NTLA) News Today

Intellia Therapeutics logo
$8.10 -0.21 (-2.47%)
Closing price 04/23/2025 03:58 PM Eastern
Extended Trading
$8.14 +0.03 (+0.37%)
As of 04/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Intellia Therapeutics, Inc. stock logo
Intellia Therapeutics (NASDAQ:NTLA) Trading Up 10.1% - Still a Buy?
Intellia Therapeutics (NASDAQ:NTLA) Trading 10.1% Higher - Here's Why
Intellia Therapeutics, Inc. stock logo
Wolfe Research Upgrades Intellia Therapeutics (NASDAQ:NTLA) to Outperform
Wolfe Research raised shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 target price on the stock in a research report on Monday.
Intellia Therapeutics, Inc. stock logo
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Rockefeller Capital Management L.P.
Rockefeller Capital Management L.P. grew its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 81.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 137,838 shares of the company'
Intellia Therapeutics, Inc. stock logo
Russell Investments Group Ltd. Has $1.37 Million Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Russell Investments Group Ltd. lessened its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 40.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 117,415 shares of the compan
Intellia Therapeutics upgraded at Wolfe on sentiment, valuation
Intellia Therapeutics, Inc. stock logo
Federated Hermes Inc. Has $45,000 Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Federated Hermes Inc. lessened its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 99.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,845 shares of the company's stock after selling
Intellia Therapeutics, Inc. stock logo
Geode Capital Management LLC Increases Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Geode Capital Management LLC increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 2.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,389,240 shares of the company's stock a
Intellia Therapeutics, Inc. stock logo
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Jump Financial LLC
Jump Financial LLC raised its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 94.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 362,637 shares of the company's stock after bu
Intellia Therapeutics, Inc. stock logo
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 4.9% - Should You Sell?
Intellia Therapeutics (NASDAQ:NTLA) Trading Down 4.9% - Time to Sell?
Intellia Therapeutics, Inc. stock logo
Alliancebernstein L.P. Lowers Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Alliancebernstein L.P. reduced its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 87.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 265,318 shares of the company's stock
Intellia Therapeutics, Inc. stock logo
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nineteen research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold rec
Intellia Therapeutics, Inc. stock logo
FIL Ltd Grows Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
FIL Ltd boosted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 737.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 159,671 shares of the company's stock after acquiring an additional 140,608 shares dur
Intellia Therapeutics, Inc. stock logo
Wellington Management Group LLP Boosts Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Wellington Management Group LLP increased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 8.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 699,814 shares of the company's stock after purchasing an additional
Intellia Therapeutics, Inc. stock logo
ExodusPoint Capital Management LP Acquires 52,486 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
ExodusPoint Capital Management LP increased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 98.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 105,827
Intellia Therapeutics, Inc. stock logo
Schroder Investment Management Group Has $274,000 Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Schroder Investment Management Group lessened its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 72.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,000 shares of the co
Intellia Therapeutics, Inc. stock logo
Vanguard Group Inc. Has $118.82 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Vanguard Group Inc. boosted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 5.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,190,053 shares of the company's s
Get Intellia Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.

NTLA Media Mentions By Week

NTLA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NTLA
News Sentiment

0.95

0.73

Average
Medical
News Sentiment

NTLA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NTLA Articles
This Week

16

11

NTLA Articles
Average Week

Get Intellia Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:NTLA) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners